Application Number: AU 2025223817
Lactiplantibacillus Plantarum JN9 Probiotic Strain and Therapeutic Formulation
This invention features the Lactiplantibacillus plantarum JN9 bacterial strain combined with an optimized formulation designed to enhance therapeutic properties and stability. The JN9 strain demonstrates superior survival rates during gastrointestinal transit and enhanced colonization of beneficial bacterial populations. The formulation includes stabilizing agents that maintain viable cell counts throughout storage and transit. The combination delivers
View the Lactiplantibacillus Plantarum JN9 Probiotic Strain and Therapeutic Formulation PDF
Download the PDF version of this Application Open to Public Inspection
This patent introduces innovative solutions addressing critical challenges in lactiplantibacillus technology. The invention combines advanced engineering principles with practical design considerations to deliver meaningful improvements in functionality, reliability, and user experience.
The Problem
Current probiotic formulations have limited therapeutic efficacy and stability challenges during storage and gastrointestinal transit. Developing probiotic strains with enhanced properties and optimized formulations is essential for expanding therapeutic and nutritional applications. The food and pharmaceutical industries need probiotic solutions with demonstrated health benefits and commercial viability.
The inability to address these challenges has limited innovation in the field and created inefficiencies that impact the broader industry. Current solutions often involve complex workarounds or compromise on performance, reliability, or user experience. This creates opportunities for transformative innovations that could reshape how these fundamental challenges are addressed.
What This Invention Does
This invention features the Lactiplantibacillus plantarum JN9 bacterial strain combined with an optimized formulation designed to enhance therapeutic properties and stability. The JN9 strain demonstrates superior survival rates during gastrointestinal transit and enhanced colonization of beneficial bacterial populations. The formulation includes stabilizing agents that maintain viable cell counts throughout storage and transit. The combination delivers superior therapeutic outcomes compared to existing probiotic products, with applications in digestive health, immune system support, and general wellness.
The comprehensive architecture ensures that all system components work in concert to deliver superior performance compared to existing solutions. The integrated approach addresses not only the primary technical challenge but also considers manufacturing efficiency, user experience, and long-term reliability across diverse operating conditions.
Key Features
- Novel JN9 Bacterial Strain. Enhanced strain selected for superior therapeutic properties and gastrointestinal survival characteristics.
- Optimized Formulation. Specialized combinations of growth media and stabilizers maximize viability and therapeutic efficacy.
- Enhanced Stability. Formulation maintains viable cell counts through storage, shipping, and gastrointestinal transit.
- Therapeutic Applications. Demonstrated benefits for digestive health, immune support, and overall wellness maintenance.
Who Is Behind It?
The patent is led by ADM (Shanghai) Management Co., Ltd., a recognized innovator headquartered in China. The invention brings together expertise from inventors Xu, Changyun; Yan, Ziqing. Patent attorney representation includes N/A.
The application was filed on 28 August 2025 with priority date 29 August 2024 in China, establishing precedent in the patent record for these technical innovations.
Why It Matters
Probiotic therapy represents a growing segment of preventive healthcare and functional food markets. Superior strains and formulations enable manufacturers to differentiate products and demonstrate meaningful health benefits to consumers. This innovation expands therapeutic applications while improving commercial product reliability and shelf life. The development is particularly valuable given the increasing consumer interest in gut health and preventive wellness.
This innovation represents a significant step forward in solving long-standing technical challenges, with implications extending beyond immediate applications. The patent reflects substantial research and development investment and demonstrates the commitment to advancing the field through systematic innovation and engineering excellence.
Related Concepts
Probiotics are live microorganisms that, when consumed in adequate amounts, confer a health benefit on the host. Specific strains like Lactiplantibacillus plantarum are selected for their resilience during gastrointestinal transit and their ability to beneficially modulate the gut microbiome.
The science of gut microbiome research has driven rapid expansion of the functional food market, with probiotic formulations increasingly recognised for their roles in digestive health, immune support, and broader preventive healthcare applications.
AU 2025223817 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.
Related Patents Open to Public Inspections
See related Patents open to public inspection.
CAR-T Cell Proliferation Method Using Specialized Lipid Particles
Electricity Generating Device
Beverage Delivery Device
Disclaimer
The information presented in this article is provided for general informational and illustrative purposes only.
Content on this page may be derived from publicly available intellectual property records, including patent documentation and related materials. While reasonable care is taken in compiling and summarising this information, ATMOSS does not guarantee the accuracy, completeness, currency, or reliability of any content presented.
This article is not a substitute for reviewing the original source documents. Patent applications, specifications, claims, and related records may contain detailed technical, legal, and contextual information that is not fully represented in this summary.
ATMOSS does not provide legal, technical, or commercial advice. Users should not rely on this content for decision-making purposes.
For authoritative and up-to-date information, users should refer directly to the official records available via IP Australia and other relevant intellectual property databases. Links to these official sources are provided where applicable.
ATMOSS accepts no liability for any loss, damage, or consequences arising from the use of, or reliance on, the information contained in this article.